Effect and Safety of Tamsulosin, the Prostate Specific ä1-Blocker, in the Treatment of BPH (Benign Prostatic Hyperplasia)

Aktuelle Urologie

Volumn 27, Issue , 1996, Pages 25-26

  Kawabe, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

BPH, blocker; Tamsulosin; 1 receptor subtype

Indexed keywords

EID: 21344471853     PISSN: 00017868     EISSN: 14388820     Source Type: Journal    
DOI: 10.1055/s-2008-1055642     Document Type: Article

References (5)

1. Homma, Y., K. Kawabe, T. Tsukamoto, O. Yamaguchi, K. Okada, Y. Aso, H. Watanabe, E. Okajima, T. Yamaguchi, Y. Ohashi: Standard criteria for diagnosis and treatment efficacy for benign prostatic hyperplasia - Therapeutic efficacy. Int. J. Urol, in print
2. Kawabe, K., N. Moriyama, S. Yamada, N. Taniguchi: Rationale for the use of α-blockers in the treatment of benign prostatic hyper-plasie (BPH). Int. I. Urol. 1 (1994) 203-211
3. Kawabe, K., A. Ueno, Y. Takimoto, et al.: Clinical evaluation of YM617 on bladder outlet obstruction associated with benign prostatic hypertrophy - A double-blind, multicenter study compared with placebo. Hinyokigeka 4 (1991) 231-242
4. 1-adrenoceptor subtypes. Naunyn-Schmiedebergs Arch. Pharmacol. 350 (1994) 136-142
5. 1-adrenoceptor antagonist binding in human prostate and aorta. Clin. Exper. Pharmacol. Physiol. 21 (1994) 405-411